Procedural and clinical outcomes of patients undergoing a TAVI in TAVI procedure: Rationale and design of the multicentre, prospective, observational ReTAVI registry.
ReTAVI registry
TAVI
aortic stenosis
redo‐
transcatheter aortic valve implantation
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
revised:
26
04
2024
received:
28
03
2024
accepted:
01
05
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Transcatheter aortic valve implantation (TAVI) is increasingly being used in younger patients and those with lower peri-procedural risk, meaning more patients will live long enough to experience structural valve deterioration (SVD) of the bioprosthesis, indicating repeated TAVI. Experience of repeated TAVI-transcatheter heart valve (THV) implantation into an index THV is limited. This registry aims to assess the peri-procedural and short-term safety, efficacy and durability of repeated TAVI. The ReTAVI Prospective observational registry is an investigator-initiated, multicentre, international, prospective registry of patients undergoing repeated TAVI using balloon-expandable SAPIEN prosthesis to evaluate procedural and short-term safety, efficacy and durability as well as anatomical and procedural factors associated with optimal results. The registry will enrol at least 150 patients across 60 high-volume centres. Patients must be ≥18 years old, have had procedural success with their first TAVI, have index THV device failure, intend to undergo repeated TAVI and be considered suitable candidates by their local Heart Team. All patients will undergo a 30-day and 12-month follow-up. The estimated study completion is 2025. The registry will collect pre-, peri-, postoperative and 12-months data on patients undergoing repeated TAVI procedures with THVs for failure of the index THV and determine VARC-3-defined efficacy and safety at 30 days and functional outcome at 12 months. The registry will expand existing data sets and identify patient characteristics/indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis.
Sections du résumé
BACKGROUND
BACKGROUND
Transcatheter aortic valve implantation (TAVI) is increasingly being used in younger patients and those with lower peri-procedural risk, meaning more patients will live long enough to experience structural valve deterioration (SVD) of the bioprosthesis, indicating repeated TAVI. Experience of repeated TAVI-transcatheter heart valve (THV) implantation into an index THV is limited. This registry aims to assess the peri-procedural and short-term safety, efficacy and durability of repeated TAVI.
METHODS
METHODS
The ReTAVI Prospective observational registry is an investigator-initiated, multicentre, international, prospective registry of patients undergoing repeated TAVI using balloon-expandable SAPIEN prosthesis to evaluate procedural and short-term safety, efficacy and durability as well as anatomical and procedural factors associated with optimal results. The registry will enrol at least 150 patients across 60 high-volume centres. Patients must be ≥18 years old, have had procedural success with their first TAVI, have index THV device failure, intend to undergo repeated TAVI and be considered suitable candidates by their local Heart Team. All patients will undergo a 30-day and 12-month follow-up. The estimated study completion is 2025.
CONCLUSIONS
CONCLUSIONS
The registry will collect pre-, peri-, postoperative and 12-months data on patients undergoing repeated TAVI procedures with THVs for failure of the index THV and determine VARC-3-defined efficacy and safety at 30 days and functional outcome at 12 months. The registry will expand existing data sets and identify patient characteristics/indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14241Subventions
Organisme : Edwards Lifesciences
Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Spadaccio C, Alkhamees K, Al‐Attar N. Recent advances in aortic valve replacement. F1000Res. 2019;8:8.
Virgili G, Romano SM, Valenti R, et al. Transcatheter aortic valve implantation in younger patients: a new challenge. Medicina (Kaunas). 2021;57(9):883.
Voigtländer L, Seiffert M. Expanding TAVI to low and intermediate risk patients. Front Cardiovasc Med. 2018;5:92.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic‐valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597‐1607.
Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic‐valve replacement in high‐risk patients. N Engl J Med. 2011;364(23):2187‐2198.
Toggweiler S, Wood DA, Rodés‐Cabau J, et al. Transcatheter valve‐in‐valve implantation for failed balloon‐expandable transcatheter aortic valves. JACC Cardiovasc Interv. 2012;5(5):571‐577.
Tarantini G, Delgado V, de Backer O, et al. Redo‐Transcatheter aortic valve implantation using the SAPIEN 3/ultra Transcatheter heart valves‐expert consensus on procedural planning and techniques. Am J Cardiol. 2023;192:228‐244.
Généreux P, Piazza N, Alu MC, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825‐1857.
Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for Transcatheter aortic valve implantation clinical trials: a consensus report from the valve academic research consortium. J Am Coll Cardiol. 2011;57(3):253‐269.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium‐2 consensus document. J Am Coll Cardiol. 2012;60(15):1438‐1454.
Erlebach M, Head SJ, Mylotte D, et al. VARC endpoint definition compliance rates in contemporary transcatheter aortic valve implantation studies. EuroIntervention. 2016;12(3):375‐380.
Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long‐term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2017;52(3):408‐417.
Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of structural valve degeneration for surgical and Transcatheter bioprosthetic aortic valves. Circulation. 2018;137(4):388‐399.
Costa G, Criscione E, Todaro D, Tamburino C, Barbanti M. Long‐term Transcatheter aortic valve durability. Interv Cardiol. 2019;14(2):62‐69.
Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10‐year outcomes of the NOTION trial. Eur Heart J. 2024;45:1116‐1124.
Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes. 2014;7:264.